|Videos|May 22, 2017

Past Infectious Disease Outbreaks Can Help Inform Zika Efforts

Jean-Paul Gonzalez, MD, PhD, Deputy Director, Center of Excellence for Emerging and Zoonotic Animal Diseases (CEEZAD), Kansas State University, Adjunct Professor, Kansas State University, explains the importance of vector control in the fight against Zika.

Jean-Paul Gonzalez, MD, PhD, Deputy Director, Center of Excellence for Emerging and Zoonotic Animal Diseases (CEEZAD), Kansas State University, Adjunct Professor, Kansas State University, explains the importance of vector control in the fight against Zika.

Interview Transcript (slightly modified for readability)

“What we’ve learned from Ebola regarding the actual pandemic of Zika is to be prepared, to be ready to fight against the evading movement [and] strategy of the Zika virus.

But, for the Zika virus, the most important [thing] is the mosquito. The mosquitoes are the vectors and eventually can be reservoirs because [they] could [cause] transatlantic transmission of the virus. It’s a very important question, how to control the mosquitoes. However, here in the US, we are used to controlling mosquitoes for West Nile [virus], so we know the strategy. So, [we can use the] same type of approach if we want to control potentially infected mosquitoes for Zika, using the same tools we were using for the West Nile, for Chikungunya, and other mosquito-transmitted diseases.”


Related to this article

Ebola Outbreak Tops 10,000 Cases as CDC Cites Spread to Kenya, Nigeria
The CDC reports the Bundibugyo virus outbreak in the Democratic Republic of the Congo (DRC) is now the second-largest Ebola outbreak on record. As of October 28, the agency counted 10,305 total confirmed cases and 4,996 total confirmed deaths. The overall risk to the American public and travelers remains low, and no cases tied to this outbreak have been confirmed in the US.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
ID Week Highlights Part 1
In this first IDWeek 2026 roundup, oral olorofim matched AmBisome in invasive aspergillosis, aztreonam-avibactam held activity as MBL-producing CRE rose, pritelivir cut hospitalizations in refractory HSV, and zelicapavir shortened RSV symptoms in high-risk adults.